Zika virus has been a recent international public health concern with outbreaks occurring in the Americas, Caribbean, and Pacific. The zoonotic infection is primarily spread to humans by the bite of an infected Aedes mosquito. The virus also can be transmitted via bodily fluids, sexual intercourse, and maternal-fetal vertical transmission. Asymptomatic presentation is common. If symptoms do occur, individuals display a low-grade fever, maculopapular rash, arthralgia, or conjunctivitis 2 to 7 d after infection. Infection is concerning due to its associated fetal effects in pregnant women and relationship with Guillain-Barre syndrome. Diagnosis should be suspected in individuals with the appropriate symptomatology and exposure history. Diagnostic tests for the Zika virus are available and vary based on symptom duration. Treatment is supportive, and surveillance is suggested for all pregnant women. Prior infection is thought to provide immunity toward future exposures. Prevention and education is key in decreasing the spread of disease.
Opioid analgesics remain a mainstay for the treatment of acute and chronic pain. The use of these agents is associated with significant side effects including addiction and gastrointestinal (GI) dysfunction. Our laboratory has previously reported on the in vivo pharmacology of 6ß‐naltrexol, an active metabolite of naltrexone and a putative neutral antagonist. The current studies assessed the in vivo pharmacology of a related compound, 6ß‐naltrexamine, which also acts as a neutral antagonist in opioid‐exposed cell systems. I.v. administration of 6ß‐naltrexamine, in male ICR mice, resulted in a time related blockade of the antinociceptive effects of i.v. hydrocodone, ID50 value (95% CI) of 2.03 (1.68–2.46) mg/kg. The antagonist had a peak effect at 60 minutes and duration of action of approximately 90 minutes in the 55°C tail‐flick test. 6ß‐naltrexamine also dose‐dependently reversed hydrocodone‐induced GI inhibition with an ID50 value (95% CI) of 4.14 (2.23–7.71) mg/kg. These results indicated that 6ß‐naltrexamine is a relatively potent opioid antagonist that exhibits a CNS/PNS potency ratio similar to naltrexone and naloxone. We are currently assessing the efficacy of 6ß‐naltrexamine in animal models of acute and chronic dependence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.